S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
15 A.I. Trading Opportunities a Day (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
15 A.I. Trading Opportunities a Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
15 A.I. Trading Opportunities a Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
15 A.I. Trading Opportunities a Day (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
15 A.I. Trading Opportunities a Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
15 A.I. Trading Opportunities a Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
15 A.I. Trading Opportunities a Day (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
15 A.I. Trading Opportunities a Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
15 A.I. Trading Opportunities a Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
China's 1st domestically made passenger plane completes maiden commercial flight
15 A.I. Trading Opportunities a Day (Ad)
In Nigeria’s hard-hit north, families seek justice as armed groups seek control
Biden and McCarthy reach a final deal to avoid US default and now must sell it to Congress
15 A.I. Trading Opportunities a Day (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
15 A.I. Trading Opportunities a Day (Ad)
'Succession' fans brace for series finale of Emmy-winning hit drama
Turkey's Erdogan wins another term as president, extends rule into 3rd decade
NASDAQ:MDGL

Madrigal Pharmaceuticals (MDGL) Competitors

$284.88
+3.29 (+1.17%)
(As of 05/26/2023 ET)
Compare
Today's Range
$278.90
▼
$288.14
50-Day Range
$231.06
▼
$312.00
52-Week Range
$57.21
▼
$322.67
Volume
214,396 shs
Average Volume
363,242 shs
Market Capitalization
$5.21 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$312.36
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

MDGL vs. ALKS, IONS, FOLD, IMGN, IRWD, GERN, DVAX, LGND, UTHR, and BMRN

Should you be buying Madrigal Pharmaceuticals stock or one of its competitors? The main competitors of Madrigal Pharmaceuticals include Alkermes (ALKS), Ionis Pharmaceuticals (IONS), Amicus Therapeutics (FOLD), ImmunoGen (IMGN), Ironwood Pharmaceuticals (IRWD), Geron (GERN), Dynavax Technologies (DVAX), Ligand Pharmaceuticals (LGND), United Therapeutics (UTHR), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "biotechnology" industry.

Madrigal Pharmaceuticals vs.

Alkermes (NASDAQ:ALKS) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, media sentiment, analyst recommendations, risk, institutional ownership, profitability, earnings and community ranking.

In the previous week, Madrigal Pharmaceuticals had 5 more articles in the media than Alkermes. MarketBeat recorded 8 mentions for Madrigal Pharmaceuticals and 3 mentions for Alkermes. Alkermes' average media sentiment score of 1.67 beat Madrigal Pharmaceuticals' score of 0.43 indicating that Alkermes is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alkermes
2 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Very Positive
Madrigal Pharmaceuticals
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

96.2% of Alkermes shares are owned by institutional investors. Comparatively, 68.0% of Madrigal Pharmaceuticals shares are owned by institutional investors. 4.8% of Alkermes shares are owned by company insiders. Comparatively, 29.7% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alkermes currently has a consensus price target of $31.67, indicating a potential upside of 8.00%. Madrigal Pharmaceuticals has a consensus price target of $312.36, indicating a potential upside of 9.65%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alkermes
0 Sell rating(s)
3 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.40
Madrigal Pharmaceuticals
0 Sell rating(s)
2 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.80

Madrigal Pharmaceuticals has a net margin of 0.00% compared to Alkermes' net margin of -14.65%. Alkermes' return on equity of -5.02% beat Madrigal Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Alkermes -14.65% -5.02% -2.69%
Madrigal Pharmaceuticals N/A -285.00% -117.65%

Alkermes has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.61, meaning that its share price is 161% less volatile than the S&P 500.

Alkermes has higher revenue and earnings than Madrigal Pharmaceuticals. Alkermes is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.11 billion4.38-$158.27 million-$0.99-29.62
Madrigal PharmaceuticalsN/AN/A-$295.35 million-$18.10-15.74

Alkermes received 235 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 70.88% of users gave Alkermes an outperform vote while only 69.54% of users gave Madrigal Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
AlkermesOutperform Votes
662
70.88%
Underperform Votes
272
29.12%
Madrigal PharmaceuticalsOutperform Votes
427
69.54%
Underperform Votes
187
30.46%

Summary

Alkermes beats Madrigal Pharmaceuticals on 10 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MDGL vs. The Competition

Export to Excel
MetricMadrigal PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$5.21B$5.81B$4.56B$6.18B
Dividend YieldN/A2.71%2.32%6.15%
P/E Ratio-15.744.0670.4011.24
Price / SalesN/A319.343,695.1886.22
Price / CashN/A20.5597.53107.27
Price / Book34.705.095.037.13
Net Income-$295.35M$188.69M$118.58M$192.91M
7 Day Performance2.99%-2.49%1.09%0.20%
1 Month Performance-8.69%1.52%1.28%1.33%
1 Year Performance314.73%17.02%19.51%-0.24%

Madrigal Pharmaceuticals Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ALKS
Alkermes
1.7716 of 5 stars		$29.78
-1.5%		$31.67
+6.3%		-4.0%$4.95B$1.11B-30.082,280
IONS
Ionis Pharmaceuticals
1.6199 of 5 stars		$42.28
+3.9%		$46.64
+10.3%		+8.3%$6.05B$575.97M-18.30660Insider Selling
High Trading Volume
FOLD
Amicus Therapeutics
2.0087 of 5 stars		$11.75
-0.4%		$15.20
+29.4%		+39.7%$3.32B$329.23M-16.79496Analyst Revision
IMGN
ImmunoGen
1.9674 of 5 stars		$13.98
-3.8%		$13.71
-1.9%		+264.6%$3.16B$108.78M-14.87106Short Interest ↓
IRWD
Ironwood Pharmaceuticals
2.2345 of 5 stars		$10.97
+1.1%		$14.00
+27.6%		-5.0%$1.69B$410.60M10.86219Analyst Report
Analyst Revision
GERN
Geron
2.0362 of 5 stars		$3.07
-2.5%		$5.00
+62.9%		+132.1%$1.56B$494,000.00-9.0369Gap Up
DVAX
Dynavax Technologies
2.4594 of 5 stars		$11.08
+0.8%		$24.00
+116.6%		-9.9%$1.41B$722.68M7.10311Positive News
LGND
Ligand Pharmaceuticals
2.5631 of 5 stars		$77.38
+2.7%		$101.67
+31.4%		-20.3%$1.34B$196.24M61.41154Analyst Upgrade
UTHR
United Therapeutics
3.1123 of 5 stars		$216.19
-1.1%		$285.82
+32.2%		-12.1%$10.13B$1.94B14.56965Positive News
BMRN
BioMarin Pharmaceutical
2.76 of 5 stars		$91.99
-0.8%		$118.65
+29.0%		+9.3%$17.27B$2.10B242.083,082

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:MDGL) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -